多靶点药物治疗肾脏疾病。
Multi-Target Drugs for Kidney Diseases.
机构信息
Drug Discovery Center and Cardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin.
Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany.
出版信息
Kidney360. 2021 Aug 2;2(10):1645-1653. doi: 10.34067/KID.0003582021. eCollection 2021 Oct 28.
Kidney diseases such as AKI, CKD, and GN can lead to dialysis and the need for kidney transplantation. The pathologies for kidney diseases are extremely complex, progress at different rates, and involve several cell types and cell signaling pathways. Complex kidney diseases require therapeutics that can act on multiple targets. In the past 10 years, design of drugs has allowed for multi-target drugs to progress quickly from concept to reality. Several multi-target drugs have been made successfully to target AA pathways and transcription factors for the treatment of inflammatory, fibrotic, and metabolic diseases. Multi-target drugs have also demonstrated great potential to treat diabetic nephropathy and fibrotic kidney disease. These drugs act by decreasing renal TGF- signaling, inflammation, mitochondrial dysfunction, and oxidative stress. There are several other recently developed multi-target drugs that have yet to be tested for their ability to combat kidney diseases. Overall, there is excellent potential for multi-target drugs that act on several cell types and signaling pathways to treat kidney diseases.
肾脏疾病，如急性肾损伤、慢性肾脏病和肾小球肾炎，可导致透析和肾脏移植的需求。肾脏疾病的病理极其复杂，进展速度不同，涉及多种细胞类型和细胞信号通路。复杂的肾脏疾病需要能够针对多个靶点的治疗药物。在过去的 10 年中，药物设计使得多靶点药物能够迅速从概念转化为现实。已经成功开发了几种多靶点药物，以针对 AA 途径和转录因子，用于治疗炎症、纤维化和代谢性疾病。多靶点药物在治疗糖尿病肾病和纤维化性肾病方面也显示出巨大的潜力。这些药物通过减少肾脏 TGF-信号、炎症、线粒体功能障碍和氧化应激来发挥作用。还有一些最近开发的多靶点药物尚未测试其治疗肾脏疾病的能力。总的来说，针对多种细胞类型和信号通路的多靶点药物治疗肾脏疾病具有巨大的潜力。
Zotero 插件